瑞巴派特联合兰索拉唑治疗早期胃癌内镜下黏膜剥离术后溃疡的效果

Effect of rebamipide combined with lansoprazole in the treatment of ulcers after endoscopic submucosal dissection for early gastric cancer

目的观察瑞巴派特联合兰索拉唑治疗早期胃癌内镜下黏膜剥离(ESD)术后溃疡的效果。方法选取2021年2月—2023年2月烟台海港医院收治的70例早期胃癌ESD术后溃疡患者,按双色球法分为对照组与观察组,每组35例。对照组采用兰索拉唑治疗,观察组在对照组基础上加用瑞巴派特治疗,2组均持续治疗1个月。比较2组临床疗效,治疗前后黏膜厚度评分、腺体密度评分、血清炎性因子[白介素-6(IL-6)、C反应蛋白(CRP)]及治疗过程中不良反应发生情况。结果观察组治疗总有效率高于对照组(97.14%vs.77.14%,χ^(2)=4.590,P=0.032)。治疗1个月后,2组黏膜厚度评分与腺体密度评分均较治疗前明显下降,且观察组低于对照组(P<0.01);2组血清IL-6、CRP水平均较治疗前明显下降,且观察组低于对照组(P<0.01)。2组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论早期胃癌ESD术后溃疡患者采用瑞巴派特联合兰索拉唑可更好地减缓胃黏膜及腺体病变程度,减轻炎性反应,增强疗效,且不会增加不良反应,安全性较高。

Objective To observe the effect of rebamipide combined with lansoprazole in the treatment of ulcers after ESD for early gastric cancer.Methods A total of 70 cases of ulcers patients after ESD for early gastric cancer admitted to Yantai Harbour Hospital from February 2021 to February 2023 were selected,and they were divided into the control group and the observation group according to the bicolor sphere method,with 35 cases in each group.The control group was treated with lansoprazole,and the observation group was treated with rebamipide based on the control group,and both groups were treated continuously for 1 month.Clinical efficacy,mucosal thickness score,gland density score,serum inflammatory factors(IL-6,CRP)before and after 1 month of treatment,and incidence of adverse reactions during treatment were compared between the two groups.Results The total effective rate of the observation group was higher than that in the control group(97.14%vs.77.14%,χ^(2)=4.590,P=0.032).After 1 month of treatment,the mucosal thickness score and gland density score in the two groups significantly decreased compared with those before treatment,and the indexes in the observation group were lower than those of the control group(P<0.01);Serum IL-6 and CRP levels in the two groups significantly decreased compared with those before treatment,and the indexes in the observation group were lower than those of the control group(P<0.01).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The use of rebamipide combined with lansoprazole in patients with ulcers after ESD for early gastric cancer can more effectively reduce gastric mucosal and glandular lesions extent,reduce inflammation,then enhance efficacy,and without increasing adverse reactions,and with higher safety.